News Image

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Provided By GlobeNewswire

Last update: Dec 10, 2024

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform.

Read more at globenewswire.com

PROQR THERAPEUTICS NV

NASDAQ:PRQR (10/31/2025, 8:08:35 PM)

Premarket: 2.77 +0.02 (+0.73%)

2.75

+0.03 (+1.1%)



Find more stocks in the Stock Screener

PRQR Latest News and Analysis

Follow ChartMill for more